Geode Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Geode Capital Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28M	Buy	979,995 +114,697	+13%	+$243K	﹤0.01%	3162
2026 Q1	$1.88M	Buy	865,298 +35,244	+4%	+$87.5K	﹤0.01%	3149
2025 Q4	$1.49M	Buy	830,054 +10,277	+1%	+$21K	﹤0.01%	3256
2025 Q3	$1.82M	Sell	819,777 -6,556	-0.8%	-$10.7K	﹤0.01%	3205
2025 Q2	$1.22M	Buy	+826,333	New	+$1.69M	﹤0.01%	3271
2024 Q2	–	Sell	-754,110	Closed	-$950K	–	4613
2024 Q1	$950K	Buy	754,110 +29,535	+4%	+$44.1K	﹤0.01%	3383
2023 Q4	$1.29M	Buy	724,575 +24,364	+3%	+$37.9K	﹤0.01%	3245
2023 Q3	$1.16M	Buy	700,211 +147,840	+27%	+$265K	﹤0.01%	3262
2023 Q2	$1.1M	Buy	+552,371	New	+$1.32M	﹤0.01%	3308

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management's PLX Position: Q2 2026 in Review

Geode Capital Management increased its Protalix BioTherapeutics (PLX) stake by 13% in Q2 2026, buying an estimated $243K and bringing the position to 979,995 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3162.

Geode Capital Management first reported a position in PLX in Q2 2023 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Geode Capital Management held 979,995 shares of Protalix BioTherapeutics worth $2.28M as of Q2 2026.
Geode Capital Management bought 114,697 Protalix BioTherapeutics shares in Q2 2026, an estimated $243K.
Protalix BioTherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3162 holding.
Geode Capital Management first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 9 quarters since.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.